Ownership and insider activity for Immunome, Inc. (IMNM): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Price
| Price | $20.31 (closing price, November 3, 2026) |
| Market Cap | $2.4B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-11 | Higgins Jack | M-Exempt | 18,000 | $24K |
| 2026-09-11 | Higgins Jack | M-Exempt | 18,000 | $24K |
| 2026-09-11 | Higgins Jack | S-Sale | 13,200 | $334K |
| 2026-09-11 | Higgins Jack | G-Gift | 8,800 | |
| 2026-08-12 | Barchas Isaac | S-Sale | 11,048 | $301K |
| 2026-08-10 | Barchas Isaac | S-Sale | 10,125 | $264K |
| 2026-08-11 | Barchas Isaac | S-Sale | 62,291 | $1.6M |
| 2026-08-06 | Barchas Isaac | S-Sale | 20,840 | $543K |
| 2026-08-07 | Barchas Isaac | S-Sale | 15,248 | $397K |
| 2026-08-04 | Horn Kinney | M-Exempt | 40,250 | $427K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $2.5M | $39.8M | $49.2M | $20.3M | $98.7M | $143.4M | $653.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $39.5M | $74.0M | 0 |
| Receivables | 0 | 0 | $850,000 | $4.3M | $847,000 | $289,000 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.1M | $3.1M | $42.9M | $56.6M | $22.6M | $144.7M | $221.3M | $660.8M |
| Property, Plant & Equipment | $2.1M | $1.7M | $1.5M | $855,000 | $965,000 | $3.6M | $14.4M | $17.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.4M | $5.1M | $44.5M | $57.9M | $24.0M | $148.5M | $240.2M | $683.2M |
| Accounts Payable | $473,000 | $548,000 | $1.2M | $3.1M | $2.4M | $3.3M | $14.2M | $3.3M |
| Short-term Debt | $225,000 | $212,000 | $479,000 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.6M | $1.7M | $3.0M | $9.7M | $7.3M | $21.8M | $54.3M | $45.0M |
| Long-term Debt | $325,000 | $113,000 | $134,000 | 0 | 0 | 0 | 0 | $3.9M |
| Total Liabilities | $29.7M | $40.7M | $3.2M | $9.7M | $7.4M | $28.7M | $59.1M | $48.8M |
| Retained Earnings | -$26.1M | -$36.6M | -$54.4M | -$79.1M | -$116.0M | -$222.8M | -$515.8M | -$728.2M |
| Total Equity | -$25.2M | -$35.6M | $41.3M | $48.2M | $16.7M | $119.9M | $181.2M | $634.3M |
| Total Debt | $1.2M | $564,000 | $613,000 | $317,000 | $291,000 | $1.6M | $4.8M | $3.9M |
| Net Debt | -$426,000 | -$2.0M | -$39.2M | -$48.9M | -$20.0M | -$136.5M | -$212.5M | -$649.6M |
| Working Capital | $550,000 | $1.5M | $39.9M | $46.9M | $15.3M | $122.9M | $167.0M | $615.8M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 15.08 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 21.61 |
Profitability
| Return on Equity | -50.56% |
| Return on Invested Capital | -51.06% |
| Return on Assets | -44.98% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLDX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of IMNM: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks